Birgitte Krogsgaard
@b_krogsgaard
MD, PhD fellow at Aarhus University Hospital, Dept. of Cardiology, Denmark. Investigating image-based coronary physiology @FAVORIIITrial
ID: 1593165084
14-07-2013 11:37:36
23 Tweet
117 Followers
64 Following
POST-PCI FUNCTIONAL ASSESSMENT - new comprehensive review @WijnsWilliam David J. Cohen, MD, MSc Jelmer Westra Niels R. Holm academic.oup.com/eurheartj/adva…
This morning, we reached a major milestone in the FAVOR III trial! Patient number 500 was enrolled by dr. Hernán Mejía-Renteria and his colleagues at Hospital Clinico San Carlos, Madrid. Beyond grateful for the collaboration! #QFR Niels R. Holm Evald Høj Christiansen Birgitte Krogsgaard HernánMR
Yesterday, prof. Gianluca Campo and his team in Ferrara enrolled patient no 1000 in the The FAVOR III trial. Ferrara is also the top enrolling center followed by Sahlgenska, Sweden and Clinique Axium, Aix-en-Provence, France. Simone Biscaglia Tebaldi Matteo Niels R. Holm
Primary endpoint of the The FAVOR III trial on QFR vs. FFR is presented on 30. October at #TCT2024 #qfr #randomizedtrial #cardiotwitter Birgitte Krogsgaard Evald Høj Christiansen Javier Escaned Gianluca Campo Dr Koltowski Greta Žiubrytė, MD, PhD candidate Martin Sejr-Hansen Ignacio J. Amat Barbara Stähli HernánMR Luigi Di Serafino
The FAVOR III trial on QFR vs FFR to be presented as LBT 30. October at #TCT2024 - Methods paper here: eurointervention.pcronline.com/article/quanti…
TCTMD Interview with Birgitte Krogsgaard William Fearon and Mamas A. Mamas on the The FAVOR III trial - LBT presentation #TCT2024 Wednesday at 11:47 EST - Details in the simultaneous publication #coronaryphysiology #randomizedtrial #cardiotwitter
It’s late breaking day! Watch Birgitte Krogsgaard from Department of Cardiology Research AUH presenting the main results of FAVOR III Europe at #TCT2024 It is 11:47 AM at main arena! Watch it online here: crfconnect.com/conference/tct…
Get ready to witness groundbreaking data @ #TCT2024! In collaboration with JAMA this session features: ✨TRISCEND II ✨ACURATE IDE ✨FAVOR III Europe ✨FLASH @arnoldgehrke Susheel Kodali, MD Michael Reardon Niels R. Holm William Fearon Neil Fam Linda Gillam MD, MPH, MACC, FASE, FAHA, FESC Juan F. Granada Mamas A. Mamas
1/x #QFR did not meet non-inferiority to FFR in the The FAVOR III trial Europe presented by Birgitte Krogsgaard The 1-year primary EP of death, MI, and unplanned revasc was 6.7% vs 4.2% in favour of FFR. 21% more study-lesions were treated- and 27% more stents were implanted with QFR due
#QFR is NOT non-inferior to #FFR. Findings from the The FAVOR III trial at #TCT2024 Department of Cardiology Research AUH Niels R. Holm Birgitte Krogsgaard Evald Høj Christiansen
FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at one year. Findings announced at #TCT2024 and published in The Lancet. thelancet.com/journals/lance… #CardioX #CardioTwitter #CardioEd #CardioResearch
Congratulations Niels R. Holm and Birgitte Krogsgaard for delivering the FAVOR III Europe Trial. Honored to provide the commentary for this presentation MIЯVΛƬ #IC ༄ ｡° Benoy Shah MD Khaled AlShaibi Nick Curzen Andrew Sharp Dr. Purvi Parwani Ritu Thamman MD Harriette Van Spall, MD MPH 🇨🇦 Julia Grapsa Juan F. Granada
A great summary of the findings in the The FAVOR III trial by TCTMD, with important comments by Mamas A. Mamas and Joost Daemen Several substudies in the pipeline - hopefully adding further insights soon. #TCT2024 #QFR #RCT #CardioTwitter
Important insights from the The FAVOR III trial . Despite a 21% increase in PCI rate when using QFR, the occurrence of MACE was higher following revascularisation deferral by QFR than by FFR. Javier Escaned Niels R. Holm Evald Høj Christiansen
Coronary revascularisation deferral based on QFR or FFR: a post-hoc analysis 🔎 of the FAVOR III Europe trial Giovanni Occhipinti & Salvatore Brugaletta review ✍️ this analysis that found that QFR-based deferral of coronary artery revascularisation resulted in a higher incidence of
